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Abstract 
To clarify the physiological role played by neutrophil lysosomal protease in cultured human umbilical vein endothelial cells 
(HUVEC), we studied the effects of cathepsins B and D released from activated polymorphonuclear leukocytes on the fibrinolytic system 
in HUVEC. Cathepsins B and D reduced the antigens of tissue-type plasminogen activator, and they increased both the antigens and the 
activity of plasminogen activator inhibitor-1. These results uggest that cathepsins B and D are involved in the thrombotic tendency, since 
they inhibited the fibrinolytic system in cultured HUVEC. 
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Tissue-type plasminogen activator (t-PA) is a highly 
specific protease that is synthesized by vascular endothe- 
lial cells and secreted into the bloodstream. This enzyme 
plays a key role in the fibrinolytic system, the system that 
constitutes the natural counterpart of the blood coagulation 
system and is responsible for the timely degradation of 
fibrin structures in blood clots and thrombi [1]. 
Plasminogen activator inhibitor-1 (PAl-l) is also syn- 
thesized by vascular endothelial cells and secreted into the 
bloodstream. This protein is the main physiological in- 
hibitor of both t-PA and urokinase-type plasminogen (u- 
PA) in plasma [2]. 
T-PA and PAI-1 synthesized in vascular endothelial 
cells are important for the regulation of the blood coagula- 
tion system in the bloodstream. 
The migration of polymorphonuclear leukocytes (PMN- 
L) into tissue is involved in the central event in the 
inflammatory esponse [3-5]. Inflammatory tissue injury is 
induced by the abnormal release of lysosomal enzymes 
such as cathepsins B, D, and G from activated PMN-L 
[6-10]. Vascular injury causes a thrombotic tendency and 
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disseminated intravascular coagulation (DIC) [11]. The 
flbrinolytic system in the bloodstream is regulated by a 
balance between t-PA and PAI-1 secreted in vascular 
endothelial cells. 
We studied the physiological role played by the PMN-L 
lysosomal proteases, cathepsins B and D, in the fibri- 
nolytic system in cultured human umbilical vein endothe- 
lial cells (HUVEC). 
Third-passage cultures of HUVEC were used; they were 
incubated in a 5% CO 2 atmosphere at37°C. Determination 
of t-PA and PAl-1 antigens and their activity in HUVEC 
was performed with enzyme-linked imrnunosorbent assay 
(ELISA) kits (Biopool Co.) and activity assay kits (SPEC- 
TROLYETM/fibrin, Biopool Co.), respectively. Briefly, 
HUVEC, grown to confluence in collagen-coated 6-well 
plates (Coming Glass Works), were then incubated for 3, 
6, 12 and 24 h in EGM-UV culture medium (Kurabo Co.) 
with cathepsin B or cathepsin D (Sigma Co.). After incu- 
bation, t-PA and PAI-1 antigens and their activity in the 
supematants were measured with the t-PA and PAI-1 
ELISA kits and the activity kits, respectively. 
As shown in Fig. 1, t-PA and PAI-1 antigen levels were 
increased, incubation time-dependently, in the cultured 
HUVEC. PAI-1 antigen levels were 41.5-, 23.8-, and 
10.6-fold the level of t-PA antigen at 3-, 6-, 12- and 24-h 
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Fig. 1. Time-dependent release t-PA and PAI-1 in cultured HUVEC. 
Values are means +S.E. of 6 experiments. 
exposure, respectively. PAI-1 activity in conditioned 
medium-treated HUVEC (controls) also was 25.36 _ 1.59, 
32.68 _ 8.83, 52.18 + 7.03 and 49.20 + 3.76 IU/ml 
(means + S.E. of 6 experiments) at 3-, 6-, 12- and 24-h 
exposure, respectively. T-PA activity was not detected in 
this study. These results suggest that t-PA activity is 
inhibited by the binding of t-PA to HUVEC [ 12,13] and/or 
by the formation of t-PA-PAI-1 complex [13,14]. 
Fig. 2 shows the dose-dependency of the effects of 
cathepsin B on t-PA and PAI-1 antigen levels in cultured 
HUVEC. In 24-h incubation, cathepsin B (5.0 U/ml)  
significantly reduced t-PA antigen levels to 35% of control 
values (Fig. 2a). Conversely, in 24-h incubation, cathepsin 
B, at 1.0 U/ml  and 5.0 U/ml, significantly increase 
PAI-1 antigen levels, 1.29-fold and 2.12-fold, respectively, 
compared with control values (Fig. 2b). In 12-h incubation, 
cathepsin B (5.0 U/ml)  induced a 1.72-fold increase over 
control values (Fig. 2b). 
As shown in Fig. 3a, the release of t-PA antigens was 
significantly (P  < 0.01) reduced with 1.0 U/ml  and 5.0 
U/ml  of cathepsin D at 12- and 24-h incubation. Fig. 3b 
shows the dose-dependency of the effects of cathepsin D 
on PAI-1 antigen levels in cultured HUVEC. Cathepsin D 
significantly (P  < 0.01) and dose-dependently stimulated 
the release of PAI-1 antigens at 0.1 U/ml,  1.0 U/ml, and 
5.0 U/ml  with both 12- and 24-h incubation, respectively. 
As shown in Fig. 4a, PAl-1 activity was increased 1.64- 
and 2.39-fold at 1.0 U/ml  and 5.0 U/ml  of cathepsin B, 
respectively, with 24-h incubation. Cathepsin D also in- 
creased PAI-1 activity, by 2.40-fold at 1.0 U/ml  and by 
2.75-fold at 5.0 U/ml  with 12-h incubation, and by 2.73- 
fold at 1.0 U/ml  and by 2.97-fold at 5.0 U/ml with 24-h 
incubation (Fig. 4b). The increase in PAI-1 activity in- 
duced by cathepsin D was greater than that induced by 
cathepsin B. Cathepsin B is a cysteine protease, and 
cathepsin D is an aspartic protease. Therefore, it seems 
likely that the differences in effects on t-PA and PAI-I 
antigen release and PAl-1 activity exerted by cathepsin B
and cathepsin D may be due to the differences in the types 
of proteases. 
Gilboa et al. [15] reported that opsonized zymosan- 
activated neutrophils inhibited fibrinolysis. Recently, it has 
been reported that a PMN-L serine protease, cathepsin G, 
inhibits the fibrinolytic system by releasing PAI-1 from 
platelets and cultured HUVEC [16]. In acute inflammation, 
stimulation of leukocytes can lead to vascular injury. 
PMN-L are the most prominent cells at inflammatory sites 
during the early stages of inflammation and are thought o 
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Fig. 2. (a) Effects of cathepsin B on t-PA release in cultured HUVEC. 
Values are means+S.E,  of 6 experiments. * P<0.01 ,  significantly 
different from control values at 24-h exposure. (b) Effects of cathepsin B
on PAI-1 release in cultured HUVEC. Values are means+S.E,  of 6 
experiments. # P < 0.01, significantly different from control values at 
12-h exposure; * P < 0.01, significantly different from control values at 
24-h exposure. 
Y. Kimura, K. Yokoi-Hayashi / Biochimica et Biophysica Acta 1310 (1996) 1-4 3 
be responsible for injury. Vascular injury evoked by acti- 
vated PMN-L occurs via at least two pathways. (1) Vascu- 
lar injury is due to PMN-.L adherence to endothelial cells, 
the formation of a protected microenviroment, the release 
of injurious inflammatory proteases such as cathepsins B, 
D and G, and elastase, and subsequent tissue injury [1]. (2) 
Vascular injury is induced by vascular obstruction brought 
about by PMN-L/PMN--L and PMN-L/endothelial cell 
adherence [2]. In this study, we found that the cysteine 
protease, cathepsin B, and the aspartic protease, cathepsin 
D, increased PAI-1 anti~gen levels and PAI-1 activity in 
cultured HUVEC, similarly to findings with the serine 
protease, cathepsin G [15]. These results suggest that 
cathepsins B and D released from activated PMN-L are 
involved in the thrombotic tendency, since these cathepsins 
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Fig. 3. (a) Effects of cathepsin D on t-PA release in cultured HUVEC. 
Values are means-I-S.E, of 6 experiments. #P<0.01 ,  significantly 
different from control values at 12-h exposure; * P < 0.01, significantly 
different from control values at 24-h exposure. (b) Effects of cathepsin D
on PAI-1 release in cultured HUVEC. Values are means+S.E, of 6 
experiments. # P < 0.01, significantly different from control values at 
12-h exposure; * P < 0.01, significantly different from control values at 
24-h exposure. 
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Fig. 4. (a) Effects of cathepsin B on PAI-1 activity in cultured HUVEC. 
Values are means-I-S.E, of 6 experiments. # P < 0.01, significantlu 
different from control values at 12-h exposure; * P < 0.01, significantly 
different from control values at 24-hr exposure. (b) Effects of cathepsin D
on PAI-1 activity in cultured HUVEC. Values are means-t-S.E, of 6 
experiments. # P < 0.01, significantly different from control values at 
12-h exposure; * P < 0.01, significantly different from control values at 
24-h exposure. 
inhibit the fibrinolytic system in cultured HUVEC by 
increasing PAI-1 antigen and PAI-1 activity, and by reduc- 
ing t-PA antigen. 
The mechanisms whereby cathepsins B and D evoke 
these effects on t-PA and PAl-1 production require further 
clarification. 
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